Oral Immunotherapy With Boiled Then Roasted Peanuts Feasible
WEDNESDAY, Jan. 11, 2023 (HealthDay News) -- Oral immunotherapy (OIT) using boiled followed by roasted peanuts is feasible and safe for treating children with peanut allergy, according to a study published online Jan. 11 in Clinical & Experimental Allergy.
Luke E. Grzeskowiak, Ph.D., from the College of Medicine and Public Health at Flinders University in Adelaide, Australia, and colleagues examined the efficacy and safety of OIT for treating peanut allergy in children using sequential doses of boiled peanuts followed by roasted peanuts. Seventy children aged 6 to 18 years with a positive history of peanut allergy underwent OIT involving sequential up-dosing with 12-hour boiled peanuts for 12 weeks, two-hour boiled peanuts for 20 weeks, and roasted peanuts for 20 weeks to a target maintenance dose of 12 peanuts/day.
The researchers found that desensitization was successfully induced in 56 participants (80 percent). Three participants withdrew due to treatment-related adverse events. Sixty-one percent of participants experienced treatment-related adverse events, for a rate of 6.58 per 1,000 OIT doses. Medication use was infrequent in association with treatment-related adverse events, with three participants (4 percent) reporting rescue epinephrine use (0.05 per 1,000 OIT doses).
"We demonstrate the safety and feasibility of a pragmatic outpatient clinic-based peanut OIT protocol utilizing reduced allergenicity boiled peanuts as an introductory step in successfully inducing desensitization in children aged 6 to 18 years with peanut allergy," the authors write.
Abstract/Full Text (subscription or payment may be required)
Related Posts
Many Young People Unaware of Risks of Oral Sex
TUESDAY, Feb. 8, 2022 (HealthDay News) -- More than half of U.S. youths report...
Los estimulantes como Ritalin podrían ser una droga de entrada para los estudiantes universitarios
VIERNES, 8 de octubre de 2021 (HealthDay News) -- En algún momento se pensó que...
California Expands Access to Free Menstrual Products in Schools
TUESDAY, Oct. 12, 2021 (HealthDay News) -- Free menstrual pads and tampons must...
AACR: Neoadjuvant, Adjuvant Durvalumab Beneficial for NSCLC
MONDAY, May 1, 2023 (HealthDay News) -- For patients with resectable non-small...